|By PR Newswire||
|March 31, 2014 07:01 PM EDT||
DUBLIN, April 1, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/hnfpj3/hiv_vaccine) has announced the addition of the "HIV Vaccine Market Opportunity & Clinical Pipeline Analysis" report to their offering.
Ever since HIV was identified as the cause for AIDS 30 years ago, the HIV virus has become one of the greatest challenges of public health facing all countries of the world. According to UNAIDS, death due to AIDS was estimated to close to 1.6 million in 2012. There were 2.3 million new HIV infections, and about 35.3 million people currently living with HIV.
Given the pace at which the HIV virus is spreading, it is most likely that AIDS would take more lives than any other infectious disease in the future years to come. Inspite of well-expanded programs of prevention and treatment which are currently enabling the stakeholders to address the illness and death associated with HIV and AIDS, the HIV vaccines is considered to be the best solution to end this disease successfully.
HIV/AIDS has become of the leading infectious disease which is taking a huge death toll across the globe, even surpassing TB and malaria. Irrespective of whether the country is developed or developing, the disease is increasingly becoming prevalent, though with serious impact in the developing countries.
It has been observed that almost nine out of every ten HIV infections are being diagnosed in the developing countries, and two-thirds are in Sub-Saharan Africa. India currently has close to 4 million infected people, which is the largest number of infected persons of any country in the world. Despite of the combating efforts, the Asian and other developing regions are increasingly feeling the heat as HIV continues to spread at a significant rate.
In recent years there have been significant breakthroughs achieved in terms of prevention and treatment of HIV/AIDS. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and an efficient vaccine, with the help of adequate funding.
Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future.
Key Topics Covered:
1. Introduction to HIV Vaccine & Mechanism
2. HIV Vaccine: Prevention & Cure
3. Why Need For HIV Vaccines?
4. Global HIV Vaccine Market Outlook
5. Research & Development Funding Scenario for HIV Vaccine
6. HIV Vaccine Market Dynamics
7. FDA Regulatory Framework for Development of HIV Vaccine
8. HIV Vaccine Clinical Trial by Phase & Country
9. Discontinued & Suspended HIV Vaccine Clinical Trial by Phase & Country
10. Competitive Landscape
- Antigen Express
- Bionor Pharma
- FIT Biotech
- Glaxo Smithkline
- Immune Response BioPharma
- Inovio Pharmaceuticals
- Sanofi Pasteur
For more information visit http://www.researchandmarkets.com/research/hnfpj3/hiv_vaccine
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets
Jul. 7, 2015 10:30 PM EDT Reads: 2,480
Jul. 7, 2015 10:15 PM EDT Reads: 1,167
Jul. 7, 2015 09:30 PM EDT Reads: 1,158
Jul. 7, 2015 08:00 PM EDT Reads: 921
Jul. 7, 2015 07:00 PM EDT Reads: 2,626
Jul. 7, 2015 07:00 PM EDT Reads: 2,663
Jul. 7, 2015 05:45 PM EDT Reads: 2,512
Jul. 7, 2015 05:00 PM EDT Reads: 2,284
Jul. 7, 2015 05:00 PM EDT Reads: 2,317
Jul. 7, 2015 05:00 PM EDT Reads: 2,501
Jul. 7, 2015 04:45 PM EDT Reads: 1,746
Jul. 7, 2015 04:15 PM EDT Reads: 833
Jul. 7, 2015 04:00 PM EDT Reads: 1,985
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, it is now feasible to create a rich desktop and tuned mobile experience with a single codebase, without compromising performance or usability.
Jul. 7, 2015 03:45 PM EDT Reads: 1,458
Jul. 7, 2015 03:45 PM EDT Reads: 1,005